Neoptolemos, J.P, et al. (2017) Comparison of Adjuvant Gemcitabine and Capecitabine with Gemcitabine Monotherapy in Patients with Resected Pancreatic Cancer (ESPAC-4): A Multicentre, Open-Label, Randomised, Phase 3 Trial. Lancet, 389, 1011-1024.
https://doi.org/10.1016/S0140-6736(16)32409-6

has been cited by the following article:

• TITLE: A New Era in the Adjuvant Treatment of Pancreatic Adenocarcinoma

  AUTHORS: Manuela Machado, Maria Leitão, Mário Fontes e Sousa, Magalhães e Helena

  KEYWORDS: Pancreatic Adenocarcinoma, Adjuvant Chemotherapy, Positive Clinical Trials

  JOURNAL NAME: Journal of Cancer Therapy, Vol.10 No.12, December 10, 2019

  ABSTRACT: Pancreatic adenocarcinoma is currently a major public health problem, being the 7th cause of death worldwide. Incidence is increasing and unfortunately nowadays the incidence is almost overlapping to mortality. The cornerstone of curative treatment is still surgery, but adjuvant treatment is critical to decreasing the risk of recurrence.